Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 4/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
| ▸ | CASK | O14936 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | GAK | O14976 | 1/20 | 0.31 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17459559 | 0.94 | KIF11 (0.32) | KIFC1KIF11ACACBCTSCHPGDS | |
| SCHEMBL17459590 | 0.87 | ITGB1 (0.34) | ACACBHPGDS | |
| SCHEMBL17459589 | 0.87 | ITGB1 (0.34) | ACACBHPGDS | |
| SCHEMBL17968902 | 0.87 | DPP4 (0.38) | KIFC1KIF11CTSKCTSCCCNE2 | |
| SCHEMBL28532732 | 0.86 | ITGB1 (0.33) | ACACBHPGDS | |
| SCHEMBL28532154 | 0.86 | CACNA1B (0.33) | ACACBITGB3ITGA2BMKNK1 | |
| SCHEMBL17459575 | 0.83 | SMYD3 (0.34) | KIFC1KIF11ACACBCTSLCTSC | |
| SCHEMBL17825497 | 0.81 | MAPT (0.43) | — | |
| SCHEMBL15037038 | 0.81 | MAPT (0.43) | — | |
| SCHEMBL17825520 | 0.81 | MAPT (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074820-B | GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112457301-A | Novel GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| EP-3172199-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | Receptos, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| WO-2016015014-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | KIFC1 4760/4885KIF11 4830/4885ACACB 3704/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | KIFC1 4760/4885KIF11 4830/4885ACACB 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.